Kjeldsen Eigil
Cancercytogenetic Section, HemoDiagnostic Laboratory, Department of Hematology, Aarhus University Hospital, Tage-Hansens Gade 2, Ent. 4A, DK-8000 Aarhus C, Denmark,
Cancers (Basel). 2017 Nov 30;9(12):165. doi: 10.3390/cancers9120165.
Aneuploidy, the presence of an abnormal number of chromosomes in a cell, is one of the most obvious differences between normal and cancer cells. There is, however, debate on how aneuploid cells arise and whether or not they are a cause or a consequence of tumorigenesis. Further, it is important to distinguish aneuploidy (the "state" of the karyotype) from chromosomal instability (CIN; the "rate" of karyotypic change). Although CIN leads to aneuploidy, not all aneuploid cells exhibit CIN. One proposed route to aneuploid cells is through an unstable tetraploid intermediate because tetraploidy promotes chromosomal aberrations and tumorigenesis. Tetraploidy or near-tetraploidy (T/NT) (81-103 chromosomes) karyotypes with or without additional structural abnormalities have been reported in acute leukemia, T-cell and B-cell lymphomas, and solid tumors. In solid tumors it has been shown that tetraploidization can occur in response to loss of telomere protection in the early stages of tumorigenesis in colon cancer, Barrett's esophagus, and breast and cervical cancers. In hematological malignancies T/NT karyotypes are rare and the role of telomere dysfunction for the induction of tetraploidization is less well characterized. To further our understanding of possible telomere dysfunction as a mechanism for tetrapolydization in hematological cancers we here characterized the chromosomal complement and measured the telomere content by interphase nuclei quantitative fluorescence in situ hybridization (iQFISH) in seven hematological cancer patients with T/NT karyotypes, and after cytogenetic remission. The patients were identified after a search in our local cytogenetic registry in the 5-year period between June 2012 and May 2017 among more than 12,000 analyzed adult patients in this period. One advantage of measuring telomere content by iQFISH is that it is a single-cell analysis so that the telomere content can be distinguished between normal karyotype cells and cells with T/NT karyotypes. We find that the telomeres are particularly short in cells with T/NT karyotypes as compared with normal cells, and in T/NT karyotypes harboring additional chromosomal aberrations as well. These findings suggest that telomere dysfunction in hematological malignancies may be a mechanism for tetraploidization and CIN.
非整倍体是指细胞中染色体数目异常,它是正常细胞与癌细胞之间最显著的差异之一。然而,关于非整倍体细胞的产生方式以及它们是肿瘤发生的原因还是结果,仍存在争议。此外,区分非整倍体(核型的“状态”)和染色体不稳定(CIN;核型变化的“速率”)很重要。虽然CIN会导致非整倍体,但并非所有非整倍体细胞都表现出CIN。一种产生非整倍体细胞的途径是通过不稳定的四倍体中间体,因为四倍体促进染色体畸变和肿瘤发生。在急性白血病、T细胞和B细胞淋巴瘤以及实体瘤中,已报道了具有或不具有额外结构异常的四倍体或近四倍体(T/NT)(81 - 103条染色体)核型。在实体瘤中,已表明在结肠癌、巴雷特食管以及乳腺癌和宫颈癌的肿瘤发生早期,端粒保护丧失可导致四倍体化。在血液系统恶性肿瘤中,T/NT核型很少见,端粒功能障碍在诱导四倍体化中的作用尚不十分清楚。为了进一步了解端粒功能障碍作为血液系统癌症中四倍体化机制的可能性,我们在此对7例具有T/NT核型的血液系统癌症患者以及细胞遗传学缓解后的患者,通过间期核定量荧光原位杂交(iQFISH)来表征染色体组成并测量端粒含量。这些患者是在2012年6月至2017年5月的5年期间,在我们当地的细胞遗传学登记处对超过12,000例在此期间分析的成年患者进行检索后确定的。通过iQFISH测量端粒含量的一个优点是它是单细胞分析,因此可以区分正常核型细胞和具有T/NT核型的细胞的端粒含量。我们发现,与正常细胞相比,具有T/NT核型的细胞中的端粒特别短,在具有额外染色体畸变的T/NT核型中也是如此。这些发现表明,血液系统恶性肿瘤中的端粒功能障碍可能是四倍体化和CIN的一种机制。